Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dapagliflozin Faces Ominous Prospect Of New Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s rejection of Bristol-Myers Squibb and AstraZeneca’s diabetes drug dapagliflozin may mean new trials are needed, which would be a blow for the drug as well as a bad sign for the new class of SGLT2 inhibitors.


Related Content

FDA Panel To Weigh Dapagliflozin Bladder Cancer, CV Safety Questions
SGLT-2 Inhibitor Dapagliflozin Gets Another Chance At FDA
2013 May Still Be A Trough Year For Bristol As New Drugs Continue To Take Hold
Cardiovascular Uncertainty Accompanies Canagliflozin To Advisory Panel
AstraZeneca Takes Impairment Charge After Olaparib, TC-5214 Setbacks
Dapagliflozin’s CV Profile Shines, But FDA Panel Review Falls On Cancer Concerns
Stringent Hepatic Monitoring Urged For Diabetes Drug Clinical Trials
Proliferation Of New Diabetes Drugs Prompts Call For Comparative Effectiveness Trials
In Deal With BI, Lilly Gets Late-Stage Diabetes Drugs
Big Pharma Tries Out New Class On The Diabetes Block: SGLT-2


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts